Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
October 17, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
Addressing Unmet Needs: The SLE Market Grows as Research and Development Flourish
October 06, 2023 06:08 ET
|
Research and Markets
Dublin, Oct. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Systemic Lupus Erythematosus (SLE) Market (by Product Type, Route of Administration, End User, & Region): Insights & Forecast with...
Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis
July 27, 2023 16:00 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with...
Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023
July 25, 2023 16:05 ET
|
Exagen Inc.
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, before...
Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-515 in Lupus
June 27, 2023 11:14 ET
|
Trethera Corporation
LOS ANGELES, June 27, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023
April 24, 2023 16:05 ET
|
Exagen Inc.
SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2023,...
Lupus Nephritis Treatment Market is expected to accumulate a value of US$ 5.67 Billion by registering a CAGR of 11% in the forecast period 2023 to 2033 | Future Market Insights, Inc.
March 17, 2023 05:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, March 17, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Lupus Nephritis Treatment Market is expected to grow at a value of 11% CAGR, according to Future Market...
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 08, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following fourth...
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
September 20, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American...
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus
September 07, 2022 17:45 ET
|
Biogen Inc.
Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with systemic lupus erythematosus (SLE) compared to...